SUMMARY The concentration of fibronectin was assessed in a variety of coagulation factor preparations. Highest concentrations of fibronectin were found in the intermediate purity factor VIII concentrates. Significant amounts were found in cryoprecipitate but high purity factor VIII concentrates contained only small amounts. For practical purposes factor IX concentrates contained no fibronectin. Qualitative estimation of fibronectin showed the presence of an abnormal slow migrating peak on 2 DIEP which was not found in normal plasma. In vivo recovery infused fibronectin was relatively low for all products studied (30-54%). The plasma half life (17-25 h) did not differ significantly depending on whether cryoprecipitate or a factor VIII concentrate was used as a source of fibronectin. No enhancement of plasma fibronectin concentrations was obtained following DDAVP infusion, venous occlusion and exercise. Plasma fibronectin concentrations and 2 DIEP patterns were unaltered following prolonged storage.
SUMMARY The concentration of fibronectin was assessed in a variety of coagulation factor preparations. Highest concentrations of fibronectin were found in the intermediate purity factor VIII concentrates. Significant amounts were found in cryoprecipitate but high purity factor VIII concentrates contained only small amounts. For practical purposes factor IX concentrates contained no fibronectin. Qualitative estimation of fibronectin showed the presence of an abnormal slow migrating peak on 2 DIEP which was not found in normal plasma. In vivo recovery infused fibronectin was relatively low for all products studied (30-54%). The plasma half life (17-25 h) did not differ significantly depending on whether cryoprecipitate or a factor VIII concentrate was used as a source of fibronectin. No enhancement of plasma fibronectin concentrations was obtained following DDAVP infusion, venous occlusion and exercise. Plasma fibronectin concentrations and 2 DIEP patterns were unaltered following prolonged storage.
Fibronectin is a dimeric a2-glycoprotein with a molecular weight of 440 000 daltons and a normal plasma concentration of 300,ug/ml in man. ' Although its functions are not completely understood, it has been shown to possess opsonic activity mediating the phagocytosis of particulate debris by the reticuloendothelial system.2 Decreased plasma concentrations have been described in patients after major surgery, trauma, starvation, burns, sepsis and in severely ill patients with evidence of disseminated intravascular coagulation.3-8 Reduced plasma concentrations may be of clinical significance since the resulting reticuloendothelial dysfunction leads to impaired circulatory clearance of particulate debris. This may lead to an accumulation of fibrin microaggregates, collagenous debris and immune complexes, all of which can result in increasing damage to the microcirculation and the vital organs.9 It has also been possible to show that: (i) patients with low fibronectin concentrations have a reduced resistance to infection;'0 (ii) experimentally the infusion of antifibronectin antibodies reduces the ability to survive shock, trauma and bum injury" and (iii) a correlation exists between fibronectin concentrations and survival in trauma patients.4
These observations would suggest that in certain clinical situations plasma fibronectin replacement Accepted for publication 16 August 1983 therapy may be of clinical benefit. Indeed, a limited number of patients with sepsis and/or disseminated intravascular coagulation have been treated with cryoprecipitate with apparent efficacy. '2 Since no purified preparation for intravenous use is currently commercially available, we have investigated the fibronectin content, both quantitatively and qualitatively, of a number of coagulation factor preparations. These in vitro studies are accompanied by data on the in vivo recovery and plasma half-life of fibronectin after the infusion of cryoprecipitate and factor VIII concentrates. In addition, we have investigated the response of plasma fibronectin concentration to exercise, I-deamino-8-D-arginine vasopressin (DDAVP) infusion and venous occlusion and studied the properties of this protein after prolonged storage.
Material and methods
Fibronectin was assayed, both quantitatively and qualitatively, in three intermediate purity factor VIII concentrates (two from commercial sources, one from NHS Elstree), a high purity factor VIII concentrate, a factor IX concentrate (Oxford), a cryoprecipitate and fresh frozen plasma (FFP).
After reconstitution according to the manufacturer s instructions all preparations were placed in a water bath at 37°C for 60 min before assay.
Plasma fibronectin was purified, from normal 1377 plasma and factor VIII concentrates, by affinity chromatography on gelatin-Sepharose as described by Engvall and Ruoslahti.'3 Bound fibronectin was eluted with 4 M urea and the resulting eluate dialysed against 0-15 M NaCl, 0.15 M sodium phosphate, pH 7.4 (PBS).
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed as described by Weber and Osbom.'4 Fibronectin concentration was determined by Laurell's electroimmunoassay'5 in 1% agarose (containing 2% rabbit antihuman fibronectin) for 18 h at 120 V using a barbital buffer system (pH 8*6, I = 0.02). Antifibronectin antibodies were prepared by immunisation of rabbits with fibronectin purified from human plasma by gelatin-Sepharose chromatography. Fibronectin (conc) x vol of concentrate infused (ml) where fibronectin (post) was the highest post infusion level of fibronectin, fibronectin (pre) was the pre infusion level of fibronectin and fibronectin (conc) was the fibronectin concentration of the two infused products.
Total protein concentration was determined using a Technicon Auto Analyser (SMAC).
Storage properties of plasma fibronectin were investigated quantitatively and qualitatively, by serially assaying aliquots of plasma stored at -70°C and -40°C (for up to 3 months) and at 4°C and 25°C (for up to 2 weeks).
To 
Results
The fibronectin and total protein concentration of the blood products studied are shown in Table 1 . The factor VIII concentrates, with the exception of the high purity preparations, contained the highest concentrations of fibronectin ranging from 2100-3600 ,ug/ml. Cryoprecipitate contained 1500 ,ug/ml whereas a high purity factor VIII concentrate, as Fibronectin in blood products-an in vitro and in vivo study centrate (NHS, Elstree) are given in Table 2 . Recovery ranged from 30-54% with no significant difference between the two preparations. The plasma half-life varied from 17-25 h. Maximum plasma concentrations of fibronectin in the five subjects studied were found immediately after infusion. On 2-DIEP plasma samples from 15 normal volunteers gave a single narrow peak (Fig. la) . This pattern was unchanged following prolonged storage at -40°C. An abnormal 2 DIEP pattern, however, was found in cryoprecipitate and factor VIII concentrates. In addition to the main peak a second slower migrating peak (Fig. lb) was found. This second peak persisted when fibronectin was separated from the factor VIII concentrates and cryoprecipitate using affinity chromatography. Fibronectin purified from the various blood products studied showed a normal pattern on SDS-PAGE (data not shown).
Fibronectin was found to be, immunologically, a very stable protein. No changes in plasma concent- Fig. 1 18 Infusion studies demonstrated a percentage recovery of infused fibronectin of only 30-54%. This is significantly lower than that reported for other proteins such as FVIII:C (>80%). '9 Sherman and Lee20 have shown in animal studies that this low recovery might be due in part to intravascular/ extravascular redistribution. However, in the present study the finding of an abnormal peak on 2 DIEP of cryoprecipitate and factor VIII concentrates suggests that a fraction of the infused fibronectin may be either denatured or circulate in a complexed form. Similar 2 DIEP patterns have recently been described in plasma from some patients with acute leukaemia and it has been suggested that the slower migrating peak might represent fibronectin complexed with fibrinogen.2' Rapid clearance of this altered fibronectin may contribute to the low recovery observed. It is, therefore, likely that the purification processes involved in the production of the blood products leads to the production of small quantities of altered fibronectin.
The recovery of fibronectin from the various blood products studied is similar despite the major methodological differences in their preparation. This data differs from that reported by Gomperts et al, '7 who claim that the infusion of cryoprecipitate results in a better recovery of fibronectin when compared to factor VIII concentrates. They suggest that this is due to denaturation of fibronectin during the preparation procedure. However, we did not find any differences when fibronectin obtained from cryoprecipitate and factor VIII concentrates was assessed by Reilly, MceVerry, Mackie Thus our results would suggest that factor VIII concentrates, with the exception of high purity preparations, are the most efficient available material for replacement therapy. Any such potential benefit must be weighed against the relative hepatitis risks22 and the recent possible association between concentrate use, immunological abnormalities and the acquired immunodeficiency syndrome (AIDS).23
It would obviously be of considerable value with regard to replacement therapy if the fibronectin plasma content could be enhanced. Two procedures investigated, DDAVP infusion and exercise, have been shown to increase the plasma concentration of certain proteins, such as FVIIIR:AG and plasminogen activator, found in endothelial cells. From a practical point of view the infusion of DDAVP to blood donors has been used to increase the yield of FVIII:C.24 We were, however, unable to show that these procedures had any significant effect on plasma fibronectin concentrations.
